Signaling Pathway
Inetetamab is a monoclonal antibody that specifically targets domain IV of the HER2 receptor. This antibody exhibits antitumor activities either as a standalone treatment or in combination with tyrosine kinase inhibitors. Inetetamab's mode of action and its specificity for the HER2 receptor make it a valuable tool in cancer research, particularly in studies focused on HER2-positive tumors.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Inetetamab is a monoclonal antibody that specifically targets domain IV of the HER2 receptor. This antibody exhibits antitumor activities either as a standalone treatment or in combination with tyrosine kinase inhibitors. Inetetamab's mode of action and its specificity for the HER2 receptor make it a valuable tool in cancer research, particularly in studies focused on HER2-positive tumors. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
